Laurie Ferguson’s Post

Interested in knowing what it's like working at Neurotech Pharmaceuticals, Inc.? Hear from employees Ralph, Alexandra, Derek, Meaghan, David and Katie to see how they are inspired every day. #mactel #retina #innovation #opportunity #teamwork #dedication

We're asking ophthalmic professionals to help us assess current opinions and business practices across the industry by filling out OWL’s 2024 Business & Leadership Trends Survey. As added motivation to take the survey, OWL will be giving away a complimentary Champion Membership (worth $500) to two lucky winners drawn from those who complete the entire survey! The survey closes on Friday July 19th, so submit your responses today ➡️ https://lnkd.in/emb8xq5f

Thomas A. Albini, MD speaks with Michael A. Singer, MD at the Retina World Congress meeting about the data he presented on NT-501, Neurotech Pharmaceuticals, Inc. for the treatment of Macular Telangiectasia (MacTel). Read the article in the Retina Minute published by Retinal Physician. #mactel #retina #ophthalmology

Neurotech Pharmaceuticals, Inc. wishes you a happy and safe 4th of July! #mactel #retina #ophthalmology

Neurotech Pharmaceuticals, Inc. Chief Medical Officer, Thomas Aaberg Jr., MD, speaks to Healio | Ocular Surgery News at the recent CTS Retina Summit where he discusses NT-501, an encapsulated cell therapy in development for macular telangiectasia type 2 “The backbone of our technology are human [retinal pigment epithelium] cells that we can genetically engineer to produce a variety of therapeutic proteins,” Aaberg said, adding that NT-501 (revakinagene taroretcel) is one such device that has been engineered to produce ciliary neurotrophic factor. #mactel #retina

As part of our continued commitment to the MacTel Type 2 community, we’re proud to announce the launch of UncoveringMacTel.com. Learn about the disease, how it is diagnosed, and how to meet its challenges in a simple, user-friendly experience. #mactel #retina #ophthalmology #raredisease

Looking for mentorship? The OWL Fellows program carefully pairs rising leaders with more established leaders in the ophthalmic space, allowing them to share experiences and grow. Apply to be an OWL Fellow today ➡️ https://bit.ly/OWLFellows

MEETING REPORTER: Octane 2024 Ophthalmology Summit: Future of Cell Therapy. Join Neurotech Pharmaceuticals, Inc. Jim Mazzo at the Octane OC 2024 Ophthalmology Summit, where leaders from diverse groups, including ophthalmologists, industry strategists, and investors, gather to discuss the future of ophthalmology. This segment features insights from a panel on cell therapy innovations, with experts Emmecell, Jeffrey L. Goldberg, MD, PhD, and Rich Small discussing breakthroughs in front and back eye treatments, including cornea, glaucoma, and retinal diseases.